NeoGenomics to Participate in Upcoming Investor Conferences
Stocks in this Quantisnow insightHealth Care
Historical context for NEO
Across the 19 sessions after earlier NEO headlines, the stock closed higher 9 times and lower 10 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NEO | SPY |
|---|---|---|---|
| Apr 29, 2026 | NeoGenomics upgraded by Leerink Partners with a new price targetand 1 other headline that session | -0.7% | -0.0% |
| Apr 23, 2026 | NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration | -3.3% | -0.4% |
| Apr 13, 2026 | NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026 | +4.0% | +1.0% |
| Apr 7, 2026 | NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026 | +0.5% | +0.0% |
| Mar 16, 2026 | NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling | +4.6% | +1.0% |
| Feb 25, 2026 | NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types | +1.8% | +0.8% |
Quantisnow market dataNASDAQ
NEO
NeoGenomics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Precision Instruments
Get push alerts for NEO
Full NEO profile on Quantisnow Follow NEO and get a push notification the moment its next story breaks.